Galimberti S - Search Results

1

Different gamma/delta T clones sustain GVM and GVH effects in multiple myeloma patients after non-myeloablative transplantation.

Galimberti S, Benedetti E, Morabito F, Petrini I, Battolla B, Papineschi F, Fazzi R, Ciabatti E, Martino M, Cuzzola M, Console G, Iacopino P, Petrini M. Galimberti S, et al. Leuk Res. 2006 May;30(5):529-35. doi: 10.1016/j.leukres.2005.09.004. Epub 2005 Oct 24. Leuk Res. 2006. PMID: 16249028

2

Peripheral blood stem cell contamination evaluated by a highly sensitive molecular method fails to predict outcome of autotransplanted multiple myeloma patients.

Galimberti S, Morabito F, Guerrini F, Palumbo GA, Azzará A, Martino M, Benedetti E, Di Raimondo F, Petrini M. Galimberti S, et al. Br J Haematol. 2003 Feb;120(3):405-12. doi: 10.1046/j.1365-2141.2003.04106.x. Br J Haematol. 2003. PMID: 12580954 Free article.

3

Evaluation of BCRP and MDR-1 co-expression by quantitative molecular assessment in AML patients.

Galimberti S, Guerrini F, Palumbo GA, Consoli U, Fazzi R, Morabito F, Santini V, Petrini M. Galimberti S, et al. Leuk Res. 2004 Apr;28(4):367-72. doi: 10.1016/j.leukres.2003.09.002. Leuk Res. 2004. PMID: 15109536

4

Prognostic role of minimal residual disease in multiple myeloma patients after non-myeloablative allogeneic transplantation.

Galimberti S, Benedetti E, Morabito F, Papineschi F, Callea V, Fazzi R, Stelitano C, Andreazzoli F, Guerrini F, Ciabatti E, Martino M, Nobile F, Iacopino P, Petrini M. Galimberti S, et al. Leuk Res. 2005 Aug;29(8):961-6. doi: 10.1016/j.leukres.2005.01.017. Leuk Res. 2005. PMID: 15978948 Clinical Trial.

5

Chimerism does not influence graft-versus-myeloma and graft-versus-host disease in reduced intensity setting.

Galimberti S, Benedetti E, Morabito F, Fazzi R, Pacini S, Andreazzoli F, Martino M, Iacopino P, Petrini M. Galimberti S, et al. Transpl Immunol. 2005 Dec;15(2):173-7. doi: 10.1016/j.trim.2005.06.002. Epub 2005 Jul 25. Transpl Immunol. 2005. PMID: 16412962

6

Response to chemotherapy and tandem autologous transplantation of multiple myeloma patients and GSTP1 and TYMS polymorphisms.

Maggini V, Buda G, Galimberti S, Conidi E, Giuliani N, Morabito F, Genestreti G, Iacopino P, Rizzoli V, Barale R, Petrini M, Rossi AM. Maggini V, et al. Among authors: galimberti s. Leuk Res. 2008 Jan;32(1):49-53. doi: 10.1016/j.leukres.2007.03.029. Epub 2007 May 23. Leuk Res. 2008. PMID: 17512053 Clinical Trial.

7

Bone and bone-marrow interactions: haematological activity of osteoblastic growth peptide (OGP)-derived carboxy-terminal pentapeptide. Mobilizing properties on white blood cells and peripheral blood stem cells in mice.

Fazzi R, Testi R, Trasciatti S, Galimberti S, Rosini S, Piras F, L'Abbate G, Conte A, Petrini M. Fazzi R, et al. Among authors: galimberti s. Leuk Res. 2002 Jan;26(1):19-27. doi: 10.1016/s0145-2126(01)00091-1. Leuk Res. 2002. PMID: 11734300

8

Bone and bone marrow interactions: hematological activity of osteoblastic growth peptide (OGP)-derived carboxy-terminal pentapeptide. II. Action on human hematopoietic stem cells.

Fazzi R, Galimberti S, Testi R, Pacini S, Trasciatti S, Rosini S, Petrini M. Fazzi R, et al. Among authors: galimberti s. Leuk Res. 2002 Sep;26(9):839-48. doi: 10.1016/s0145-2126(02)00008-5. Leuk Res. 2002. PMID: 12127560

9

Bone and bone marrow interactions: hematological activity of osteoblastic growth peptide (OGP)-derived carboxy-terminal pentapeptide III. Action on human megakaryocytopoiesis: focus on essential thrombocythemia.

Fazzi R, Galimberti S, Pacini S, Testi R, Azzarà A, Orciuolo E, Trombi L, Metelli MR, Petrini M. Fazzi R, et al. Among authors: galimberti s. Leuk Res. 2004 Oct;28(10):1097-105. doi: 10.1016/j.leukres.2004.01.019. Leuk Res. 2004. PMID: 15289024

10

Quantitative molecular evaluation of minimal residual disease in patients with chronic lymphocytic leukemia: efficacy of in vivo purging by alemtuzumab (Campath-1H).

Galimberti S, Cervetti G, Cecconi N, Fazzi R, Pacini S, Guerrini F, Manetti C, Caracciolo F, Petrini M. Galimberti S, et al. J Immunother. 2004 Sep-Oct;27(5):389-93. doi: 10.1097/00002371-200409000-00007. J Immunother. 2004. PMID: 15314547 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

444 results

Search Page